ADCs as a Chemistry-Driven Delivery System
An antibody-drug conjugate (ADC) combines biological targeting with small-molecule potency. The antibody is designed to recognize a tumor-associated antigen. The payload provides the cell-killing or cell-modulating activity. The linker connects the two and controls how stable the conjugate is in circulation and how the payload is released after the ADC reaches the target cell.
That simple description hides a complex development problem. ADC performance depends on antigen biology, antibody selection, linker design, payload properties, conjugation site, drug-to-antibody ratio (DAR), formulation and analytical control. A strong ADC program therefore needs coordinated biology and chemistry rather than a payload simply attached to an antibody.
For chemistry teams, the most important lesson is that the linker-payload system is not a secondary detail. It determines plasma stability, release behavior, impurity profile, hydrophobicity, aggregation risk and the identity of the active species delivered inside the cell.
The Core Architecture: Antibody, Linker, Payload
Every ADC can be understood through three connected design elements plus the conjugation strategy that joins them.
| Design element | Main role | Chemistry questions |
|---|---|---|
| Antibody | Antigen recognition, circulation and internalization | Does the target internalize? Does the antibody tolerate modification? |
| Linker | Stability and controlled release | What trigger releases the payload? What species is released? |
| Payload | Potent activity after delivery | Is it potent enough? Can it be attached without losing activity? |
| Conjugation site | Attachment of linker-payload to antibody | How uniform is the product? How is DAR controlled? |
The antibody provides selectivity, but it does not solve the full delivery problem by itself. The linker and payload must remain stable during manufacturing, storage and circulation, then provide the right release profile after internalization or antibody degradation.
Linker Chemistry: Cleavable and Non-Cleavable Strategies
ADC linkers are commonly grouped into cleavable and non-cleavable designs.
Cleavable linkers are designed to respond to a biological trigger. Common examples include protease-cleavable linkers, disulfide linkers that respond to a reducing environment, and acid-sensitive linkers that respond to lower pH. These designs can release a payload species that may diffuse into neighboring cells, which is relevant to the bystander effect.
Non-cleavable linkers rely on antibody degradation to release a payload-linker residue. These designs can offer strong plasma stability, but the released species is often more polar and less membrane-permeable. That can reduce bystander activity while improving control over where the payload is released.
| Linker approach | Release concept | Development consideration |
|---|---|---|
| Protease-cleavable | Triggered by lysosomal enzymes | Common in ADC design; release profile depends on linker-payload structure. |
| Redox-sensitive | Triggered by intracellular reducing conditions | Useful for controlled release but sensitive to stability design. |
| Acid-sensitive | Triggered by acidic compartments | Requires careful plasma stability evaluation. |
| Non-cleavable | Released after antibody catabolism | Often stable in circulation; released payload residue may be less membrane-permeable. |
Payload Selection and DAR Control
ADC payloads are usually highly potent because only a portion of the administered conjugate reaches antigen-positive cells. Historically important payload classes include microtubule inhibitors and DNA-damaging agents. Topoisomerase I inhibitors have also become prominent in modern ADC design. Newer programs continue to explore payloads beyond classic cytotoxins.
Payload selection is closely tied to linker and conjugation design. A payload must carry a chemical handle that allows attachment, tolerate the conjugation conditions, remain stable as part of the linker-payload intermediate and release an active species in the intended cellular environment.
DAR is another critical quality attribute. A low DAR may reduce potency. A high DAR can increase hydrophobicity, aggregation, clearance and toxicity risk. Modern ADC development therefore focuses not only on the average DAR but also on the distribution of conjugated species.
Mechanism of Action: From Binding to Payload Release
The mechanism of action can be viewed as a sequence of events:
- The antibody binds an antigen on the target-cell surface.
- The ADC-antigen complex is internalized.
- The internalized ADC traffics through endosomal and lysosomal compartments.
- The linker is cleaved or the antibody is degraded, depending on linker design.
- The payload or payload-linker residue reaches its intracellular target.
- If the released species is membrane-permeable, it may contribute to a bystander effect in nearby cells.
Failure at any step can weaken the whole design. A potent payload cannot compensate for poor internalization. A stable linker is not useful if it does not release the right active species. A high DAR is not an advantage if it drives aggregation or fast clearance.
Material and Analytical Needs in ADC Development
ADC programs create specialized material needs long before final drug manufacturing. Teams may need payload intermediates, cleavable and non-cleavable linkers, self-immolative spacers, hydrophilic linker units, maleimide or click-chemistry handles, site-specific conjugation reagents and impurity reference standards.
Analytical control is equally important. Linker-payload intermediates, free payload, deconjugated species, positional isomers and conjugation-related impurities can all become development questions. Reference standards and orthogonal analytical methods help teams understand these risks earlier.
CHEMOS focuses on this upstream material layer: custom payload intermediates, linker chemistry, conjugation handles, ADC-related building blocks and analytical reference compounds for feasibility, optimization and process-development work.
Where ADC Design Is Moving
The ADC field continues to expand beyond a single design template. Current development directions include more selective tumor antigens, improved linker stability, site-specific conjugation, Fc engineering, combination strategies, pathology-based biomarker selection and computational tools for matching payload, linker and target biology.
For chemistry teams, this means ADC development will continue to require adaptable linker-payload design, careful impurity control and reliable access to non-standard materials.
FAQ
What is an antibody-drug conjugate?
An antibody-drug conjugate is a targeted therapeutic format that links an antibody to a potent payload through a chemical linker. The antibody provides targeting, while the linker and payload determine release behavior and intracellular activity.
What are the main parts of an ADC?
The main parts are the antibody, linker and payload. The conjugation site and DAR distribution are also critical because they affect uniformity, stability, clearance and activity.
What is the difference between cleavable and non-cleavable linkers?
Cleavable linkers respond to triggers such as lysosomal enzymes, reducing conditions or low pH. Non-cleavable linkers release payload-linker residues after antibody degradation.
Why is DAR important?
DAR is the average number of payload molecules attached to each antibody. It affects potency, aggregation, pharmacokinetics and safety risk, so both the average value and distribution need to be controlled.
What materials do ADC programs commonly need?
Programs often need payload intermediates, linker units, self-immolative spacers, conjugation handles, hydrophilic modifiers and analytical reference standards for linker-, payload- and conjugation-related impurities.
How can CHEMOS support ADC research?
CHEMOS can support research and process-development teams with custom synthesis of ADC-related building blocks, linker-payload intermediates, conjugation handles and analytical reference compounds.
Notice
This article is for research and technical information purposes only. It is not intended as medical, regulatory or legal advice. Materials and technologies discussed should be used according to applicable research-use, safety and regulatory requirements.
References and Further Reading
- Cheung A, Liu Y, Chenoweth AM, Montaseri H, Esapa B, Chudasama V, Baker JR, Thurston DE, Karagiannis SN. Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond. Physiological Reviews, 2026, 106(3), 1681-1756. https://doi.org/10.1152/physrev.00039.2025
- Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nature Reviews Drug Discovery, 2017. https://doi.org/10.1038/nrd.2016.268
- Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nature Reviews Clinical Oncology, 2021. https://doi.org/10.1038/s41571-021-00470-8
- Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduction and Targeted Therapy, 2022. https://doi.org/10.1038/s41392-022-00947-7
- FDA. Clinical Pharmacology Considerations for Antibody-Drug Conjugates: Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-antibody-drug-conjugates-guidance-industry